Lakefront Biotherapeutics American Depositary Shares
LKFT
82 hedge funds and large institutions have $894M invested in Lakefront Biotherapeutics American Depositary Shares in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
6% more funds holding
Funds holding: 77 → 82 (+5)
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
4% less capital invested
Capital invested by funds: $932M → $894M (-$37.7M)
1.48% less ownership
Funds ownership: 15.16% → 13.68% (-1.5%)
37% less call options, than puts
Call options by funds: $1.28M | Put options by funds: $2.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$9.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$4.6M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$4.57M |
| 4 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$2.83M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$72.3M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$12.9M |
| 3 |
Goldman Sachs
New York
|
-$11.4M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.3M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.09M |
LKFT Hedge Fund Activity: Q1 2018 in Review
82 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2018, worth a combined $894M — down 4% from $932M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LKFT positions and 8 closed out — a net gain of 7 holders — while 28 added to existing stakes and 26 trimmed.
The largest buyer was Credit Suisse, adding an estimated $9.4M. The largest seller was Fidelity Investments, cutting an estimated $72.3M.
- 82 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2018, up from 77 in Q4 2017.
- Funds reported $894M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2018, down 4% quarter-over-quarter.
- 15 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2018 and 8 closed out, a net change of +7 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2018 was Credit Suisse, an estimated $9.4M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2018 was Fidelity Investments, an estimated $72.3M sold.
Based on aggregated 13F filings for Q1 2018.